Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy

Risk Assessment of Febrile Neutropenia and Grade 3-4 Neutropenia in Patients With Non-hematological Cancer Treated With Conventional Chemotherapy

NCT01799421 ·Status: COMPLETED

A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer

NCT00277160 ·Status: COMPLETED ·Phase: PHASE4

Treatment for Elderly Patients With High Risk Breast Cancer

NCT00117910 ·Status: COMPLETED ·Phase: PHASE3

Various G-CSF Regimens to Prevent Infection During Chemotherapy

NCT00536081 ·Status: COMPLETED ·Phase: PHASE3

Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia

NCT01918241 ·Status: UNKNOWN ·Phase: PHASE2

Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer

NCT04174742 ·Status: RECRUITING

Efficacy, Safety and Cost-effectiveness of PEG-rhG-CSF for Primary vs Secondary Prophylaxis

NCT03701841 ·Status: UNKNOWN

A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's Lymphoma

NCT00117455 ·Status: COMPLETED ·Phase: PHASE2

A Study of Neutropenia and Anemia Management in Patients With Solid Tumors Receiving Myelotoxic Chemotherapy

NCT00883181 ·Status: COMPLETED

PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia

NCT02996617 ·Status: UNKNOWN ·Phase: PHASE4

Study on the Incidence of Febrile Episodes During Stem Cells Collection After Chemotherapy in Patients With Multiple Myeloma

NCT00932217 ·Status: UNKNOWN ·Phase: PHASE3

Home Administration of NivestimTM in the Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia

NCT02956967 ·Status: COMPLETED

Effectiveness of Reduced GCSF Dosing in Patients With a Low to Moderate Risk of Febrile Neutropenia

NCT01658956 ·Status: UNKNOWN ·Phase: PHASE2

Safety and Effectiveness Assessment of PeGagen® (Pegfilgrastim) in the Prevention of Chemotherapy-induced FN

NCT04460079 ·Status: COMPLETED

Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)

NCT00115414 ·Status: COMPLETED ·Phase: PHASE2

Antimicrobial Revision in Persistent Febrile Neutropenia

NCT05784844 ·Status: WITHDRAWN ·Phase: PHASE4

An Observational Study to Evaluate the Safety and Efficacy of Pegfilgrastim (Neulasta®)

NCT03433560 ·Status: COMPLETED

Distinction Risk of Severe Infection in Febrile Neutropenia After Chemotherapy

NCT03434795 ·Status: COMPLETED

Pegfilgrastim-gema Compared to Pegfilgrastim-roche for Prevention of Induced Neutropenia in Breast Cancer Patients.

NCT03404752 ·Status: UNKNOWN ·Phase: PHASE3

The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy

NCT02905916 ·Status: UNKNOWN ·Phase: PHASE4

Fever and Neutropenia in Pediatric Oncology Patients

NCT03768869 ·Status: WITHDRAWN ·Phase: PHASE3

Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer

NCT04009941 ·Status: COMPLETED ·Phase: PHASE4

The Efficacy and Safety of PEG-rhG-CSF in Preventing Chemotherapy-induced Neutropenia

NCT02761460 ·Status: UNKNOWN ·Phase: PHASE3

Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia

NCT03559387 ·Status: TERMINATED ·Phase: PHASE2

Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lymphoma

NCT00115193 ·Status: COMPLETED ·Phase: PHASE2